Lysophosphatidic acid (LPA) is a small ubiquitous lipid found in vertebrate and
nonvertebrate organisms that mediates diverse biological actions and demonstrates …

Lysophosphatidic acid (LPA), a bioactive phospholipid, and its family of cognate G protein-
coupled receptors have demonstrated roles in many biological functions in the nervous …

Endothelial differentiation gene (Edg) proteins are G-protein-coupled receptors activated by
lysophospholipid mediators: sphingosine-1-phosphate (S1P) or lysophosphatidic acid. We …

Abstract Objective FTY720, a sphingosine‐1‐phosphate (S1P) receptor agonist that crosses
the blood–brain barrier, is a potential immuno‐therapy for multiple sclerosis. Our objective …

CNS white matter is subject to a novel form of neural plasticity which has been termed
“myelin plasticity”. It is well established that oligodendrocyte generation and the addition of …

Overcoming remyelination failure is a major goal of new therapies for demyelinating
diseases like multiple sclerosis. LINGO-1, a key negative regulator of myelination, is a …

Lysophosphatidic acid (LPA) is a potent lipid mediator that evokes a variety of biological
responses in many cell types via its specific G protein-coupled receptors. In particular, LPA …

Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) regulate a diverse range
of mammalian cell processes, largely through engaging multiple G protein-coupled …

Fingolimod is a sphingosine-1-phosphate (S1P) analogue that has been used in clinical
trials as a systemic immunomodulatory therapy for multiple sclerosis. Fingolimod readily …

The molecular mechanisms used by oligodendrocyte precursor cells (OPCs),
oligodendrocytes (OLs), and Schwann cells (SCs) to advance processes for motility in the …